

Translumina Therapeutics announces initiation of direct operations in UAE

September 24, 2024 | News

To make its product portfolio reach every corner of the world



Translumina Therapeutics, one of India's largest domestic players in the coronary stents market, has announced the initiation of direct operations in the United Arab Emirates (UAE).

Translumina was incorporated in 2011 as a sales & marketing company specialising in coronary intervention devices. Since its inception, the company has successfully established their own manufacturing capabilities and developed in-house product lines, which are endorsed by interventional cardiologists worldwide.

"At Translumina, we have a clear ambition to put India on the global map for medical devices and fulfil our national vision of 'Make in India, Make for the world'. Indian engineering & innovation will be at the forefront of the medical devices industry, and the launch of our direct presence in the UAE is a step in that direction," remarked Gurmit Singh Chugh, Co-Founder and Chairman of Translumina Therapeutics.

Echoing this sentiment, Punita Sharma Arora, Co-Founder & Vice-Chairman of Translumina, added, "We've been present in international markets for more than five years now and have built up a strong direct presence in Europe & South Asia. In just the last one year, we have invested in a direct presence LATAM & SEA, and now with the addition of the MENA region, we have full conviction that our comprehensive product portfolio will be able to reach every corner of the world."

The company's drug-eluting stent (DES) technologies have been developed through a technological collaboration with German Heart Centre, which has led to the development of groundbreaking medical devices, including the world's longest-studied DES, with over 10 years of safety and efficacy data.